Geron Corporation’s Imetelstat: A Promising Treatment in Phase 3 Trials for Myelodysplastic Syndrome and Myelofibrosis
Geron Corporation is advancing Imetelstat, a first-in-class telomerase inhibitor, through Phase 3 clinical trials targeting myelodysplastic syndromes (MDS) and myelofibrosis (MF). Below, we discuss the progress and potential impact of this promising treatment.
Myelodysplastic Syndromes (MDS)
The IMerge Phase 3 trial evaluated imetelstat in lower-risk MDS patients who are transfusion-dependent and have not responded to erythropoiesis-stimulating agents. Top-line results demonstrated that imetelstat met the primary endpoint, achieving a statistically significant 8-week transfusion independence (TI) rate of 39.8% compared to 15.0% with placebo. Additionally, the 24-week TI rate was 28.0% for imetelstat versus 3.3% for placebo. These findings suggest that imetelstat can provide meaningful and durable transfusion independence for patients with lower-risk MDS.
In March 2024, an FDA advisory panel voted 12-to-2 in favor of imetelstat, stating that its benefits outweigh the associated risks. The panel acknowledged manageable toxicities and recognized the significance of the treatment, given limited existing options. The FDA’s decision on approval is anticipated by June 16, 2024.
Myelofibrosis (MF)
The IMpactMF Phase 3 trial is assessing imetelstat in patients with relapsed or refractory MF. This study is notable for evaluating overall survival as the primary endpoint, a first in MF clinical trials. As of December 2023, the trial had reached 50% enrollment, with an interim analysis expected in the first half of 2025 and final results anticipated in the first half of 2026.
Safety Profile
Imetelstat’s safety profile includes manageable hematologic toxicities, primarily neutropenia and thrombocytopenia, which are typically reversible and can be managed with dose modifications. The FDA advisory panel acknowledged these concerns but deemed them manageable within the context of the treatment’s benefits.
Conclusion
Imetelstat has shown promise in providing durable transfusion independence for lower-risk MDS patients and is under investigation for potential survival benefits in MF patients. Pending regulatory approvals, imetelstat could offer a new therapeutic option for patients with these hematologic malignancies.
Sources:
You must be logged in to post a comment.